Up until the present, there are no predictive biomarkers or indicators for guiding the HNSCC treatment. A survey report on precision medicine entitled, “Global Precision Medicine Market – Analysis and Forecast, 2017–2026” from BIS research registered $43.59 billion in 2016. It is estimated to reach $141.70 billion by 2026, with an annual growth rate of 11.23%. The Personalized Medicine Coalition for diagnostic and targeted agents was $25 billion in 2015.
“On a thumb rule, 30% of new Cancer screened cases would account for HNSCC, the majority of men affected by it.”Dr Hemantkumar Nemade
Consultant Head and Neck Oncologist
The biomarkers for precision medicine drugs (in numbers) were 5 in 2008 and went up to 132 in 2016. According to a survey by The Tufts Centre for Drug Development. 42% of drugs are in the pipeline plan and will be considered soon. Global investments in the next 5 years are likely to increase by 33% for precision medicine drugs, and immunotherapy drugs. There is a surge in the global market where the growth was $108 billion in 2016 and is nearly estimated to be $200 billion by 2021 . . .